Parse Biosciences, Inc.

Parse Biosciences, Inc., a for-profit manufacturer of single-cell RNA sequencing reagents and benchtop automation equipment headquartered in Seattle, Washington, operates exclusively as a prime contractor on small-dollar federal purchase orders, competing full-and-open with no set-aside designations across civilian research agencies. The company is foreign-owned and sells specialized biotechnology consumables and instruments to support genomic research programs at the National Institutes of Health, the Environmental Protection Agency, and related federal science agencies.

Parse Biosciences' federal footprint consists entirely of prime awards — twelve purchase orders totaling $279 thousand in combined potential value, though cumulative obligations across those awards reach $504 thousand, indicating repeat procurements or contract modifications that exceed initial ceiling values. The company's customer base clusters heavily within HHS-NIH. The National Institute of Allergy and Infectious Diseases leads by award count (three purchase orders, $45 thousand combined potential value) for Evercode sequencing reagent kits and single-cell RNA and T-cell receptor sequencing reagents supporting infectious disease research. The National Institute of Neurological Disorders and Stroke and the NIH Office of Acquisitions anchor the largest individual awards: a $68.2 thousand purchase order (September 2024) for an Integra Automation Bundle supporting single-cell RNA sequencing workflow scaling, and a $67 thousand purchase order (July 2026) for an Evercode WT Mega Benchtop Pipetting Robot and associated reagents supporting standardized hematology testing at the National Institute of Mental Health's Molecular Imaging Branch. The Environmental Protection Agency Office of Research and Development accounts for two purchase orders ($37 thousand combined) for Parse Biosciences kits supporting CCTE (Center for Computational Toxicology and Exposure) research. The top five customer agencies by potential value cover 86% of recent dollars; this concentration reflects Parse Biosciences' narrow positioning as a specialized reagent and instrument supplier to federally funded life-science research rather than a broad-based vendor.

Activity has accelerated sharply — one award each in 2022 and 2023, then six awards in 2024 — with two awards in 2025 and one in 2026. Award sizes are consistently sub-seventy-thousand-dollar purchase orders executed under simplified acquisition authority (FAR 12.603 and FAR Subpart 13). One purchase order valued at $67 thousand reaches completion inside the next twenty-four months. The company holds no subcontract positions and does not anchor any IDIQs, GWACs, or BPAs; all federal work is direct prime provision of proprietary Evercode reagent kits, UDI plate technology, and Integra automation bundles for single-cell genomics research.